Skip to main content
. Author manuscript; available in PMC: 2011 Oct 28.
Published in final edited form as: Cancer Lett. 2010 May 5;296(2):233–240. doi: 10.1016/j.canlet.2010.04.014

Figure 1. SNDX-275 and melphalan synergistically inhibit proliferation/survival of MM cells.

Figure 1

A, Human MM cells (RPMI8226) were plated onto 96-well plates with complete culture medium (RPMI1640, 10% FBS). After 24 hrs, the medium was replaced with control medium (fresh RPMI1640, 0.5% FBS) or same medium containing indicated concentrations of SNDX-275, melphalan, or combinations of SNDX-275 and melphalan for another 72 hrs incubation. The percentages of surviving cells from each treatment to controls, defined as 100% survival, were determined by reduction of MTS. Data shows the representative of at least three independent experiments. * P<0.002 vs combination of SNDX-275 and melphalan. B, Dose-effect curves were generated with Chou-Talalay equation of statistical analysis. C, The combination index (CI) curves were calculated according to the Chou-Talalay equation.